To characterise the specific transcriptional profile that affect the different clinical phenotypes of meningiomas in NF2 patients compared to sporadic NF2-altered meningiomas, we first investigated the messenger RNA (mRNA) expression profiles of 29 primary WHO grade I meningiomas (14 grade I meningiomas in 14 NF2 patients versus 15 grade I sporadic NF2-altered meningiomas) (Additional file 1: Figures S1, S2A-C, Additional file 2: Table S3). The gene discussed is NF2; the disease is meningioma.